Related Experiment Video
Updated: Feb 19, 2026
09:43
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
8.5K
Summary
Patient-derived xenografts (PDX) show significant genomic changes over time. These alterations may impact their reliability for predicting cancer drug response in personalized medicine.
Area of Science:
- Oncology
- Genomics
- Translational Research
Background:
- Patient-derived xenografts (PDX) are crucial preclinical models in cancer research.
- Understanding the genomic stability of PDX models is vital for their accurate application.
Purpose of the Study:
- To investigate the longitudinal genomic alterations in patient-derived xenografts (PDX).
- To assess the implications of observed genomic changes on the predictive value of PDX models for personalized medicine.
Main Methods:
- Analysis of genomic data from 1,110 patient-derived xenografts.
- Study encompassed 24 distinct cancer types.
- Longitudinal assessment of genomic landscape evolution.
Main Results:
- Significant temporal genomic heterogeneity was observed across PDX models.
- Specific genetic alterations linked to drug sensitivity were identified.
- Genomic evolution raises concerns regarding PDX model fidelity over time.
Conclusions:
- The dynamic genomic nature of PDX models necessitates careful consideration.
- PDX models may require re-evaluation for predicting drug response in personalized cancer therapy.
